Luminary Therapeutics

1:30 PM - 1:45 PM (EST), Monday, February 6, 2023 ・ Music Box
Luminary is a clinical stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and or TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique are that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T-Cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with 3 antigen receptors specifically designed to overcome antigen escape.

Company Type:
Privately Funded Company
Company HQ State:
Minnesota
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
BAFF CAR
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
President & CEO
Luminary Therapeutics